|
|
|
| Application effect of intravenous thrombolysis with recombinant tissuetype plasminogen activator combined with interventional therapy in patients with acute ischemic stroke |
| SUN Yongjin PIAO Xiangyu |
| Department of Neurology,Zhongshan Hospital Affiliated to Dalian University,Liaoning Province,Dalian 116001,China |
|
|
|
|
Abstract Objective To investigate the application effect of intravenous thrombolysis with recombinant tissue-type plasminogen activator combined with interventional therapy in patients with acute ischemic stroke.Methods A total of 100 patients with acute ischemic stroke in Zhongshan Hospital Affiliated to Dalian University from January 2018 to may 2021 were selected as the research object.They were divided into the control group (50 cases) and the observation group (50 cases) according to the random number table method.The patients in the control group received intravenous thrombolysis with recombinant tissue-type plasminogen activator,the patients in the observation group received intravenous thrombolysis with recombinant tissue-type plasminogen activator combined with interventional therapy.The clinical efficacy,the severity of dysfunction (modified Rankin scale [MRS]),the ability of self-care (modified Barthel index [MBI]),the level of cerebral hemodynamics before and after treatment and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant (P＜0.05).Before treatment,there were no significant differences in the MRS score,MBI score,cerebral blood flow velocity,minimum blood flow and dynamic impedance between the two groups (P＞0.05).After treatment,the MRS score of the observation group was lower than that of the control group,the MBI score,cerebral blood flow velocity,minimum blood flow and dynamic impedance in the observation group were higher than those in the control group,the differences were statistically significant (P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05).Conclusion Intravenous thrombolytic therapy with recombinant tissue-type plasminogen activator combined with interventional therapy has a good effect on patients with acute ischemic stroke,which can significantly improve their functional disorders and cerebral hemodynamic indexes,and promote the recovery of self-care ability,with fewer adverse reactions,and has a higher clinical promotion value.
|
|
|
|
|
|
| [1] |
谭冉，邓立普.急性缺血性脑卒中损伤机制及其治疗药物研究新进展[J].医学食疗与健康，2021，19（18）：206-208.
|
| [2] |
曹猛，宋学梅，梁丽，等.急性缺血性脑卒中后吞咽障碍发病率及影响因素分析[J].护理学杂志，2021，36（2）：24-27.
|
| [3] |
邹东勇，蒋波.rt-PA 静脉溶栓联合人尿激肽原酶治疗急性缺血性脑卒中的效果及对预后的影响[J].中外医学研究，2020，18（10）：44-46.
|
| [4] |
陈静，谢闯洲.神经介入联合阿替普酶静脉溶栓对急性缺血性脑卒中患者脑血流动力学及神经功能的影响[J].海南医学，2020，31（5）：579-581.
|
| [5] |
中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，51（9）：666-682.
|
| [6] |
路雅宁，吴跃华，林黎明.NIHSS 评分对急性脑梗死的评估效力研究[J].国际老年医学杂志，2017，38（3）：131-132，封3.
|
| [7] |
翟萌萌，王建平，余列，等.中性粒细胞与淋巴细胞比值对急性脑梗死患者预后的预测价值[J].中国脑血管病杂志，2017，14（2）：82-86.
|
| [8] |
曾小雁，贺婕，苏微微，等.不同潜伏期体感诱发电位在脑梗死患者预后评价中的价值比较[J].检验医学与临床，2016，13（1）：120-122.
|
| [9] |
何悦，徐宇浩，杨溢，等.头颈部动脉粥样硬化狭窄与急性缺血性脑卒中患者7 d 神经功能恶化的相关性[J].中国实用神经疾病杂志，2021，24（19）：1703-1712.
|
| [10] |
张填，陈薪旭，王埮.缺血性卒中后认知障碍与脑梗死分型及相关危险因素的关系[J].中国实验诊断学，2020，24（4）：543-548.
|
| [11] |
吕洋，高思山，滕继军.高龄急性缺血性脑卒中患者重组组织型纤溶酶原激活剂静脉溶栓的有效性和安全性分析[J].中国医师杂志，2021，23（3）：440-443.
|
| [12] |
徐七，陈芳芳，耿德勤.急性缺血性脑卒中患者rt-PA 静脉溶栓治疗预后的影响因素研究[J].中国临床神经科学，2020，28（2）：158-162.
|
| [13] |
涂雪松.急性缺血性脑卒中血管介入治疗方法和装置的研究进展[J].中国临床神经科学，2020，28（1）：85-92.
|
| [14] |
殷涛，韩靖，赵腾跃.介入治疗血管内溶栓联合机械取栓对急性缺血性脑卒中患者脑血管血流状态及预后的影响[J].中国医刊，2020，55（7）：757-761.
|
| [15] |
朱好春，葛晗明，赵航.重组组织型纤溶酶原激活物静脉溶栓联合神经介入治疗对急性轻型缺血性脑卒中老年患者的临床效果[J].中国临床实用医学，2020，11（4）：52-54.
|
|
|
|
